In healthy cells, the BRAF protein helps to control or regulate cell growth in the lungs and other areas of the body. It works with another protein, known as MEK, to control cell growth and ...

The three-drug regimen – based on Array BioPharma/Pierre Fabre’s BRAF inhibitor Braftovi (encorafenib) and MEK inhibitor Mektovi (binimetinib) along with Eli Lilly’s EGFR-targeted antibody E ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

The original agreement last year focused on melanoma patients who are receiving BRAF/MEK combination therapies – specifically Novartis' Tafinlar (dabrafenib) and Mekinist (trametinib ...

Drawing upon these findings, other researchers suggested that combining BRAF inhibitors with another treatment type known as MEK inhibitors could improve outcomes compared to selective BRAF inhibitors ...

BRAF positive melanoma produces too much of a protein called BRAF. This also affects other proteins such as MEK. Both of these can make the cancer grow. Targeted cancer drugs work by blocking the ...

They include RAF inhibitors, such as sorafenib and vemurafenib, or MEK inhibitors such as selumetinib (AZD6244). Since trials investigating the potential use of anti-BRAF agents in the management ...

The combination of Hsp90 inhibitors with RAF or MEK inhibitors may achieve a better pathway inhibition in RAS and/or BRAF mutant tumors. This work will contribute significantly toward better patient ...